Stefan Wiemann
Overview
Explore the profile of Stefan Wiemann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
148
Citations
4999
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vlachavas E, Voutetakis K, Kosmidou V, Tsikalakis S, Roditis S, Pateas K, et al.
Mol Oncol
. 2025 Jan;
PMID: 39876058
Colorectal cancer (CRC) patients with microsatellite-stable (MSS) tumors are mostly treated with chemotherapy. Clinical benefits of targeted therapies depend on mutational states and tumor location. Many tumors carry mutations in...
2.
Bai S, Herrera-Abreu M, Rohn J, Racine V, Tajadura V, Suryavanshi N, et al.
BMC Biol
. 2024 Oct;
22(1):228.
PMID: 39390519
No abstract available.
3.
Rivas-Delgado A, Lopez C, Clot G, Nadeu F, Grau M, Frigola G, et al.
Hemasphere
. 2024 Oct;
8(10):e70024.
PMID: 39380845
Testicular large B-cell lymphoma (TLBCL) is an infrequent and aggressive lymphoma arising in an immune-privileged site and has recently been recognized as a distinct entity from diffuse large B-cell lymphoma...
4.
Machine Learning-Supported Diagnosis of Small Blue Round Cell Sarcomas Using Targeted RNA Sequencing
Schlieben L, Carta M, Moskalev E, Stohr R, Metzler M, Besendorfer M, et al.
J Mol Diagn
. 2024 Feb;
26(5):387-398.
PMID: 38395409
Small blue round cell sarcomas (SBRCSs) are a heterogeneous group of tumors with overlapping morphologic features but markedly varying prognosis. They are characterized by distinct chromosomal alterations, particularly rearrangements leading...
5.
Gedik M, Saatci O, Oberholtzer N, Uner M, Caliskan O, Cetin M, et al.
Cancer Res
. 2024 Feb;
84(9):1475-1490.
PMID: 38319231
Significance: Loss of induction of immunogenic cell death in response to T-DM1 leads to resistance that can be overcome by targeting TACC3, providing an attractive strategy to improve the efficacy...
6.
Montero-Vergara J, Plachetta K, Kinch L, Bernhardt S, Kashyap K, Levine B, et al.
Cell Death Dis
. 2024 Jan;
15(1):14.
PMID: 38182563
GRB2 is an adaptor protein of HER2 (and several other tyrosine kinases), which we identified as a novel BECN1 (Beclin 1) interacting partner. GRB2 co-immunoprecipitated with BECN1 in several breast...
7.
Beumers L, Vlachavas E, Borgoni S, Schwarzmuller L, Penso-Dolfin L, Michels B, et al.
NPJ Breast Cancer
. 2023 Dec;
9(1):97.
PMID: 38042915
Intratumoral heterogeneity impacts the success or failure of anti-cancer therapies. Here, we investigated the evolution and mechanistic heterogeneity in clonal populations of cell models for estrogen receptor positive breast cancer....
8.
Gedik M, Saatci O, Oberholtzer N, Uner M, Akbulut O, Cetin M, et al.
bioRxiv
. 2023 Sep;
PMID: 37745348
Immunogenic cell death (ICD), an immune-priming form of cell death, has been shown to be induced by several different anti-cancer therapies. Despite being the first and one of the most...
9.
Noronha A, Nataraj N, Lee J, Zhitomirsky B, Oren Y, Oster S, et al.
Cancer Discov
. 2022 Jul;
12(11):2666-2683.
PMID: 35895872
Significance: EGFR-mutant lung cancers treated with kinase inhibitors often evolve resistance due to secondary mutations. We report that in similarity to the bacterial SOS response stimulated by antibiotics, endogenous mutators...
10.
Li X, Michels B, Tosun O, Jung J, Kappes J, Ibing S, et al.
J Exp Clin Cancer Res
. 2022 Jun;
41(1):190.
PMID: 35655310
Background: MicroRNAs (miRNAs) and isomiRs play important roles in tumorigenesis as essential regulators of gene expression. 5'isomiRs exhibit a shifted seed sequence compared to the canonical miRNA, resulting in different...